Cardio-metabolic parameters are associated with genetic admixture estimates in a pediatric population from Colombia

Angélica M Muñoz1,2, Claudia M Velásquez3, Gabriel Bedoya4

  • 1Research Group on Food and Human Nutrition, Universidad de Antioquia (UdeA), Calle 70 No. 52-21, Medellín, Colombia. angelicamariamc@yahoo.com.

BMC Genetics
|June 29, 2016
PubMed

Insights

Ancestry impacts cardio-metabolic health in Colombian youth. Amerindian ancestry is linked to higher triglycerides, while African ancestry increases systolic blood pressure risk, and European ancestry may be protective.

Area of Science:

  • Genetics
  • Cardiology
  • Metabolic Health

Background:

  • Cardio-metabolic parameters exhibit diverse genetic patterns across populations.
  • Ancestral genetic components (Amerindian, European, African) influence susceptibility to cardio-metabolic disorders in admixed Latin American populations.

Purpose of the Study:

  • To investigate the impact of ancestral genetic composition on cardio-metabolic risk factors in young, admixed Colombians.

Main Methods:

  • Analysis of 853 Colombian youth (10-18 years old) using 40 autosomal ancestry-informative markers (AIMs).
  • Assessment of associations between European (mean 66.6%), African (mean 14%), and Amerindian (mean 19.4%) ancestral components and various cardio-metabolic risk factors.

Main Results:

  • Triglyceride levels showed a nominal association with Amerindian ancestry (OR=1.06).
  • Systolic blood pressure was nominally associated with European (OR=0.93) and African (OR=1.07) ancestry.
  • Insulin levels and insulin resistance were associated with African ancestry.

Conclusions:

  • Amerindian ancestry may increase triglyceride risk; African ancestry may increase systolic blood pressure risk.
  • European ancestry might offer protection against high systolic blood pressure in this population.
  • Further validation in larger cohorts is recommended.
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
98
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
79
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
313
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
96
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
898